RALLYBIO CORP (RLYB) Stock Price & Overview
NASDAQ:RLYB • US75120L2097
Current stock price
The current stock price of RLYB is 8.67 USD. Today RLYB is down by -4.83%. In the past month the price increased by 48.71%. In the past year, price increased by 69.31%.
RLYB Key Statistics
- Market Cap
- 45.864M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.59
- Dividend Yield
- N/A
RLYB Stock Performance
RLYB Stock Chart
RLYB Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to RLYB. When comparing the yearly performance of all stocks, RLYB is one of the better performing stocks in the market, outperforming 94.47% of all stocks.
RLYB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RLYB. No worries on liquidiy or solvency for RLYB as it has an excellent financial health rating, but there are worries on the profitability.
RLYB Earnings
On March 16, 2026 RLYB reported an EPS of -1.03 and a revenue of 222.00K. The company beat EPS expectations (13.94% surprise) and beat revenue expectations (63.24% surprise).
RLYB Forecast & Estimates
10 analysts have analysed RLYB and the average price target is 8.16 USD. This implies a price decrease of -5.88% is expected in the next year compared to the current price of 8.67.
For the next year, analysts expect an EPS growth of 11.88% and a revenue growth -100% for RLYB
RLYB Groups
Sector & Classification
RLYB Financial Highlights
Over the last trailing twelve months RLYB reported a non-GAAP Earnings per Share(EPS) of -5.59. The EPS increased by 48.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.42% | ||
| ROE | -15.49% | ||
| Debt/Equity | 0 |
RLYB Ownership
RLYB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 362.351B | ||
| AMGN | AMGEN INC | 15.27 | 188.551B | ||
| GILD | GILEAD SCIENCES INC | 15.62 | 170.497B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.14 | 114.627B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.86 | 77.866B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 41.29 | 40.669B | ||
| INSM | INSMED INC | N/A | 31.035B | ||
| NTRA | NATERA INC | N/A | 28.359B | ||
| BIIB | BIOGEN INC | 11.44 | 26.951B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.81 | 22.845B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| EXAS | EXACT SCIENCES CORP | 345.14 | 20.026B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.149B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RLYB
Company Profile
Rallybio Corp is a US-based company operating in Biotechnology industry. The company is headquartered in New Haven, Connecticut and currently employs 15 full-time employees. The company went IPO on 2021-07-29. Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
Company Info
IPO: 2021-07-29
RALLYBIO CORP
234 Church Street, Suite 1020
New Haven CONNECTICUT US
CEO: Martin W. Mackay
Employees: 15
Phone: 13026365400
RALLYBIO CORP / RLYB FAQ
What does RLYB do?
Rallybio Corp is a US-based company operating in Biotechnology industry. The company is headquartered in New Haven, Connecticut and currently employs 15 full-time employees. The company went IPO on 2021-07-29. Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. The company has a pipeline of product candidates aimed at addressing diseases with unmet medical need in the areas of complement dysregulation and hematology. The Company’s lead program, RLYB116, is a differentiated C5 inhibitor with the potential to treat diseases of complement dysregulation, with an initial focus on immune platelet transfusion refractoriness (PTR) and refractory antiphospholipid syndrome (APS). RLYB116 is a novel, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload. Its RLYB114 is a pegylated C5 inhibitor in development for complement-mediated ophthalmic disorders.
What is the current price of RLYB stock?
The current stock price of RLYB is 8.67 USD. The price decreased by -4.83% in the last trading session.
Does RLYB stock pay dividends?
RLYB does not pay a dividend.
How is the ChartMill rating for RALLYBIO CORP?
RLYB has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting RLYB stock to perform?
10 analysts have analysed RLYB and the average price target is 8.16 USD. This implies a price decrease of -5.88% is expected in the next year compared to the current price of 8.67.